

EXTENDED REPORT

Effectiveness of a measurement feedback system on outcome in rheumatoid arthritis: a controlled clinical trial

J Fransen, G Stucki, J Twisk, A-M Chamot, J-C Gerster, T Langenegger, M Seitz, B A Michel, and the members of the Swiss Clinical Quality Management in Rheumatoid Arthritis (SCQM)

Ann Rheum Dis 2003;62:624–629

See end of article for authors' affiliations

Correspondence to:
Dr J Fransen, Department of Rheumatology, University Medical Centre Nijmegen, PO Box 9101, NL-6500 HB Nijmegen, The Netherlands; j.fransen@reuma.azn.nl

Accepted
30 November 2002

Background: With the help of a measurement feedback system, the treatment strategy for individual patients with rheumatoid arthritis (RA) can be adjusted to achieve optimal control of disease activity.

Objective: To study whether a measurement feedback system is effective in reducing disease activity in patients with RA.

Methods: Forty eight rheumatologists and 264 patients participated in a controlled clinical trial. A three month control period was followed by a 12 month period, where feedback on disease activity, disability, and damage was provided to the rheumatologist. The primary outcome measure was the rheumatoid arthritis disease activity index (RADAI).

Results: The feedback system was used for 142/228 (62%) patients. Disease modifying antirheumatic drug changes occurred in 69/169 (41%) patients. In patients with high disease activity and feedback use (n=70), the RADAI decreased in the feedback period by -0.27 points per 30 days (p<0.05), as compared with the control period. Patients for whom the feedback system was used had a better outcome than non-users.

Conclusion: Much more training on the use of a feedback system and outcome measures, as well as the inclusion of explicit treatment guidelines will be necessary to increase the clinical use of measurement feedback and, possibly, to reduce disease activity for a larger number of patients with RA.

Management of patients with rheumatoid arthritis (RA) is challenging and poses specific problems. RA has a major impact on function and quality of life. It frequently affects patients in their most productive years, and thus, disability results in a major economic loss. The cornerstone of RA management is the control of disease activity to alleviate pain, maintain function, and avoid or slow the rate of joint damage.¹ There is general agreement that rheumatoid disease activity should be controlled as soon as possible, as completely as possible, and that this control should be maintained for as long as possible, consistent with patient safety.² Unfortunately, even with the disease modifying antirheumatic drugs (DMARDs) and "biological" drugs nowadays available, complete remission or optimal control of disease activity is not achieved in all patients. Further, for individual patients, it cannot be predicted with enough certainty how the course of the disease will develop, if adverse events will occur, and if response or remission will be attained. Thus, we are still challenged to optimise the management of patients with RA.

In 1997 the Swiss Clinical Quality Management in RA (SCQM) was introduced.¹ In the Swiss healthcare system, people have as much direct access to a rheumatologist, as to the general practitioner. The SCQM provides a measurement feedback system with which rheumatologists and their patients can monitor the course of RA disease activity, disability, and joint damage.³ Rheumatologists collect standardised clinical, laboratory, and patient data, and send them to a national coordination centre, where the data are processed in a computer and a feedback report is returned (fig 1). With the help of the measurement feedback system, the individual treatment strategy can be adjusted to "titrate" RA disease activity until remission is reached or disease activity is optimally controlled.¹ Until now, the effectiveness of such a measurement feedback system in RA has not been the subject of research.

The objective of this trial was to study in patients with RA, whether (a) the measurement feedback system is effective in reducing disease activity, and (b) the levels of joint damage and disability are consequently maintained or reduced.

PATIENTS AND METHODS

Design

The study was designed as a controlled clinical trial with patients serving as their own controls. A three month control period, where disease activity was assessed without feedback, was followed by a 12 month period, where feedback to the rheumatologist was provided. It was suggested that the control period would provide an estimate for a stable course of disease activity, and that disease activity would show a reduction in the feedback period as compared with the control period. As a consequence of reduced disease activity, it was expected that the development of disability and joint damage during the feedback period would remain stable, or even improve.

Recruitment

Rheumatologists from the rheumatology departments of the five university hospitals, six regional hospitals, and from two rheumatological practices throughout Switzerland agreed to participate. Patients were recruited during 1997–98. The rheumatologists asked consecutive patients with RA (according to

Abbreviations: CDSS, computerised decision support systems; DAS28, disease activity score; DMARDs, disease modifying antirheumatic drugs; ESR, erythrocyte sedimentation rate; HAQ, Health Assessment Questionnaire; RA, rheumatoid arthritis; RADAI, rheumatoid arthritis disease activity index; RCT, randomised controlled trial; SCQM, Swiss Clinical Quality Management




Figure 1 The feedback report shown covers the serial visits of a patient with RA from 3 May 2000 to 10 February 2001. In the upper part of the report the courses over time of the DAS28, ESR, RADAI, pain (0–10 numerical rating scale), HAQ, and the Ratingen x ray score (x ray) are depicted. The HAQ is on a scale from 0 to 3; the other measures are (re)scaled to range from 0 to 10. The first table summarises the information of the measures shown in the graph. The second table contains information on concurrent drug prescriptions. It can be seen that in this patient the DAS and the HAQ decreased, whereas the x ray score did not increase further after changes in salazopyrin and infliximab treatment.

Measure	03.05.00	02.08.00	01.10.00	24.10.00	07.12.00	10.02.01
DAS	6.6	4.6	5.1	4.6	3.4	2.6
ESR	22	10	18	18	4	2
RADAI	7.0	3.5	4.4	4.4	3.3	2.9
Pain	8	4	5	5	3	3
HAQ	2.5		2.0			1.8
x Ray (%)	5		14			11

Drug	03.05.00	02.08.00	01.10.00	24.10.00	07.12.00	10.02.01
Prednisolone	10	10	10	10	10	10
Methotrexate	20	20	20	20	20	20
Salazopyrin	1000	1000	1000			
Infliximab				216	216	216

the American College of Rheumatology criteria) to participate in self assessment of disease activity for a period of three months.

Control period

When the patients agreed to participate, they were sent the rheumatoid arthritis disease activity index (RADAI) questionnaire on signs and symptoms in RA, once a month, for three months.⁴ However, when according to the rheumatologist a change in DMARD treatment appeared to be necessary, the control period was stopped and the procedure for the feedback period started immediately.

Feedback period

The start of the feedback period was scheduled at the fourth month. The patient was informed by the rheumatologist about participation in the measurement feedback system. To be included in the study the patient had to provide written informed consent. In that case, the RADAI from the control period were sent to the coordination centre and stored for later analysis. At the start the rheumatologists collected the following data: joint counts, erythrocyte sedimentation rate (ESR), current drug use, radiographs of the hands and feet (not older than six months), and patient assessed disease activity (RADAI), disability (Stanford Health Assessment Questionnaire (HAQ)),⁵ sociodemographic variables, and comorbidities. These data were then sent to the coordination centre, where the data were processed and a feedback report was returned within 10 days (fig 1). For the feedback period, the

rheumatologists were advised to monitor disease activity either with every DMARD change or, at the least, every three months. For monitoring, disease activity was assessed by the rheumatologist (disease activity score (DAS28)),⁶ and by the patient (RADAI). An updated feedback report was sent automatically when the rheumatologist sent those data to the coordination centre. After 12 months, the last study visit was scheduled, which was identical to the starting visit.

Drop outs

Patients were excluded from the analysis if (a) a change in DMARD treatment in the control period was necessary (to avoid influencing the doctors the patients were excluded after completion of the study); (b) the assessments of the control period were missing.

Measurements

The rheumatologists were provided with standardised information on how to perform the joint counts and how to handle the questionnaires. At the coordination centre, the data were checked for completeness and appropriateness before entry. Ambiguities were solved by a telephone call.

The DAS28 was calculated from the results of the 28 swollen joint count, the 28 tender joint count, and ESR.⁶ The DAS28 ranges virtually from 0 to 10. A DAS28 <3.2 is regarded as low level disease activity, a DAS28 of 3.2–5.1 as moderate, and a DAS28 >5.1 as high level disease activity.⁷ The RADAI is a five item patient assessed questionnaire, including arthritis pain, past and current global disease activity, duration of

Table 1 Population characteristics at baseline. Values are mean (SD); median (interquartile range); number (column percentage)

	Included	Drop outs	p Value
Patients, No	228	36	
Female, No (%)	156 (68)	32 (89)	0.01
Age (years), mean (SD)	59 (13)	60 (15)	0.81
TS (years), median (IQR)	12 (6–18)	9 (4–15)	0.15
TD (years), median (IQR)	11 (4–17)	8 (4–14)	0.30
RF+, No (%)	161/201 (80)	27/32 (84)	0.57
ANA+, No (%)	73/190 (38)	7/30 (23)	0.12
Pain, median (IQR)	3 (1–5)	4 (2–6)	0.32
RADAI, mean (SD)	3.5 (2.0)	3.8 (1.8)	0.47
DAS28, mean (SD)	4.1 (1.5)	4.4 (1.2)	0.19
HAQ, median (IQR)	1.0 (0.4–1.8)	1.1 (0.5–1.5)	0.49
x Ray score, median (IQR)	3 (0–12)	1 (0–21)	0.71

TS, time since symptom onset; TD, time since diagnosis; RF+, rheumatoid factor positivity; ANA+, antinuclear antibody positivity. RADAI, rheumatoid arthritis disease activity index; DAS28, disease activity index; HAQ, Health Assessment Questionnaire; x Ray, Ratingen x ray score.

morning stiffness, and a tender joint list.⁴ The RADAI ranges from 0 to 10, where higher values are indicative of higher levels of RA disease activity. The RADAI has been shown to be reliable, valid, and responsive for the assessment of disease activity in RA.^{8–10} The pain item is an 11 item numerical rating scale. The disability index of the HAQ contains 20 questions about difficulties experienced with eight activities of daily living, and four questions about the assistance used to perform these.⁵ The HAQ is scored from 0 to 3, where higher values are indicative of more difficulties when performing activities of daily living. Joint damage was scored from radiographs of the hands and feet by readers unaware of the study allocation, using the Ratingen x ray score.¹¹ The scoring of the wrist joint was modified by scoring it as a single joint, instead of as four joints. The x ray score ranges from 0 to 160, where higher scores are indicative of more and larger erosions of the joint surface.

The patient provided sociodemographic information and information about comorbidities on standardised questionnaires.¹² All questionnaires were provided in the language preferred by the patient: German, French, or Italian.

Statistical analysis

Data from intermediate monitoring visits during the feedback period were not the subject of analysis, as need-driven visits can overestimate the levels of disease activity during this period. Consequently, there were five study time points: three in the control period, two in the feedback period.

The time course of the RADAI scores in the control period was compared with the course in the feedback period, using a continuous by class regression model with random coefficients (intercept and time effect) for patients.^{13,14} The procedure thus accounts for repeated measurements on the same subjects. To account for the clustering of patients of individual rheumatologists, random coefficients (intercept and time effect) for rheumatologists were added.

Changes during the feedback period of disease activity (DAS28), patient perceived pain, disability (HAQ), and joint damage (x ray score) were analysed using paired *t* tests and 95% confidence intervals.

It was suggested in advance, that the results might be influenced by the level of disease activity in the control period, and whether measurement feedback was used during the feedback period. Accordingly, four subgroups were formed: (a) patients with low disease activity in the control period (RADAI score below the median) and no use of feedback (the rheumatologist had acquired no feedback reports); (b) low disease activity and feedback use (one or more feedback report

acquired); (c) high disease activity in the control period (RADAI score of median or higher) and no use of feedback; (d) high disease activity and feedback use. The regression analysis and the analysis of before-after differences were repeated as subgroup analysis; differences between subgroups (contrasts) were tested using Scheffe's procedure.¹⁵

To indicate DMARD changes during the feedback period, the drug at the start of the feedback period was compared with the drug at the end. The information from intermediate visits was not used, to prevent information bias through underreporting in the non-use group.

Data were stored in an Access 7.0 relational database (Microsoft Corporation, Redmond, USA) and analysed using SAS 8.1 (SAS Institute Inc, Cary, NC, USA). The research protocol was approved by the responsible Swiss medical ethical committee (UREK).

RESULTS

Sample

Forty eight rheumatologists enrolled 264 patients; 36 patients were drop outs (table 1). The RADAI scores and number of drop outs were similar between patients included by private practices, regional hospitals, or university hospitals. Reasons for dropping out were: because of DMARD change in the control period (n=33), and because all RADAI in the control period were missing (n=3). No relevant differences on prognostic and outcome variables between drop outs and patients who completed the study were found (table 1). At the end of the feedback period, 38 patients were lost to follow up. These patients were not regarded as drop outs.

Response and feedback use

The response in the control period varied between 55% and 65% for each time point. At the end of the feedback period, 190/228 (83%) patients took part in the last study visit. During the feedback period, feedback reports were acquired by the rheumatologists for 142/228 (62%) patients. Of those, 90/142 (63%) patients had one feedback report, 52/142 (37%) had 2–5 feedback reports. For the remaining 86/228 (38%) patients, the rheumatologists obtained only the report that marked the start of the feedback period.

Was disease activity stable in the control period?

The group mean (SD) RADAI scores at the three time points in the control period were 3.6 (2.0), 3.7 (2.1), and 3.7 (2.1), respectively. According to the regression model, that is correcting for within-person dependencies, the RADAI scores

Table 2 Difference between control and feedback period of the course of the RADAI over time

	No	Intercept		Control period time effect		Feedback period time effect		Difference	
		β 0	95% CI	β (C)	95% CI	β (F)	95% CI	β (C) – β (F)	95% CI
Total	228	3.27***	(2.91 to 3.63)	-0.008 ^{NS}	(-0.12 to 0.11)	-0.067***	(-0.095 to -0.039)	-0.059 ^{NS}	(-0.177 to 0.058)
Subgroups									
Low DA, no use	45	2.07***	(1.67 to 2.47)	-0.033 ^{NS}	(-0.24 to 0.17)	-0.015 ^{NS}	(-0.057 to 0.026)	0.017 ^{NS}	(-0.18 to 0.22)
Low DA, use	72	2.08***	(1.75 to 2.40)	-0.016 ^{NS}	(-0.25 to 0.22)	-0.011 ^{NS}	(-0.071 to 0.049)	0.0054 ^{NS}	(-0.23 to 0.24)
High DA, no use	41	4.76***	(4.33 to 5.19)	-0.003 ^{NS}	(-0.21 to 0.20)	-0.10***	(-0.15 to -0.053)	-0.097 ^{NS}	(-0.29 to 0.10)
High DA, use	70	4.94***	(4.59 to 5.30)	0.076 ^{NS}	(-0.15 to 0.30)	-0.19***	(-0.26 to -0.12)	-0.27*	(-0.49 to -0.041)

β 0 denotes the mean RADAI score at study start. β (C) and β (F) denote the monthly change in RADAI. NS, $p > 0.05$; * $p \leq 0.05$; ** $p < 0.001$; *** $p < 0.0001$. RADAI, rheumatoid arthritis disease activity index; DA, disease activity. See "Patients and methods" for subgroup definitions.

Table 3 Subgroup analysis of changes in estimators of disease activity, disability, and joint damage in the feedback period

	No	Δ DAS28		Δ Pain		Δ HAQ		Δ x Ray score	
		Mean	95% CI	Mean	95% CI	Mean	95% CI	Mean	95% CI
Total	190	-0.3***	(-0.5 to -0.2)	-0.6**	(-1.0 to -0.3)	-0.05	(-0.11 to 0.01)	6.7***	(4.6 to 8.8)
Low DA, no use	38	-0.2	(-0.6 to 0.2)	-0.2	(-0.9 to 0.6)	0.05**	(-0.09 to 0.20)	6.2**	(2.8 to 9.7)
Low DA, use	64	-0.3*	(-0.6 to 0.005)	-0.3	(-0.8 to 0.3)	-0.01	(-0.10 to 0.08)	5.5**	(2.4 to 8.6)
High DA, no use	30	-0.4	(-1.0 to 0.2)	-1.4*	(-2.5 to -0.3)	-0.06	(-0.21 to 0.07)	13.1*	(4.7 to 21.4)
High DA, use	58	-0.4**	(-0.7 to -0.1)	-0.9*	(-1.7 to -0.2)	-0.14*	(-0.3 to -0.04)	5.4*	(1.0 to 9.8)

* $p \leq 0.05$; ** $p < 0.001$; *** $p < 0.0001$.

DAS28, disease activity score; HAQ, disability index of the Health Assessment Questionnaire; x Ray, Ratingen x ray score; DA, disease activity. See "Patients and methods" for subgroup definitions.

Table 4 Changes in DMARD treatment at one year follow up

Subgroup	Follow up (n)	None missing (n)	DMARD changes			
			No change No (%)	Dose reduced No (%)	Dose increased No (%)	Changed No (%)
1) Low DA, no use	38	33	22 (67)	2 (6)	5 (15)	4 (12)
2) Low DA, use	64	60	37 (62)	8 (13)	10 (17)	5 (8)
3) High DA, no use	30	23	9 (39)	5 (22)	5 (22)	4 (17)
4) High DA, use	58	53	32 (60)	5 (9)	7 (13)	9 (17)
Total	190	169	100 (59)	20 (12)	27 (16)	22 (13)

The percentages were calculated for the none missing numbers in each subgroup; in 89% of the 190 patients at follow up, drug information was complete (none missing).

did not significantly change over time: β time = -0.008 (95%CI -0.12 to 0.11); $p = 0.89$ (table 2).

Was disease activity reduced in the feedback period?

The random time effect for rheumatologists was omitted from the continuous by class model, because its associated variance did not significantly differ from 0 (not shown). The time effect in the feedback period was -0.067 per 30 days (table 2), which corresponds to a mean reduction of about 0.8 RADAI points over 12 months. The reduction in RADAI in the feedback period was statistically significant. However, the time effect in the feedback period was not significantly different from the time effect in the control period.

Subgroup analysis

The regression model was subjected to subgroup analysis; the results are shown in the lower part of table 2. The "level of disease activity" in the control period and "feedback use" in the feedback period were not associated, (χ^2 ; $p = 0.81$). The difference in time effects was significant in the subgroup with relatively high disease activity in the control period and feedback use in the feedback period ($p = 0.02$). The time effect of that subgroup corresponds with a mean reduction in RADAI

score over 12 months of more than three points. Between both subgroups with high disease activity ($n = 111$), the contrast between the difference in time effects of the "use" and "no use" group was at the limit of significance: $p = 0.051$.

How did disability and joint damage develop?

During the feedback period, disease activity (DAS28) and pain decreased, disability (HAQ) did not significantly change, but joint damage (x ray score) increased (table 3). The subgroup with high disease activity and feedback use, showed significant and favourable changes in DAS28, pain, and HAQ (table 3). Their increase in the x ray score was comparably small; it was largest in the subgroup with high disease activity and no feedback use. None of the differences (contrasts) between the subgroups were statistically significant.

Did changes in drug treatment occur?

The drug changes during the feedback period could only be registered from the patients who were not lost to follow up and had complete drug information (table 4). At the start of the feedback period, 32/228 (14%) patients had no DMARD treatment, and 20 (9%) patients had a combination treatment of two or three DMARDs. More than half of the prescriptions

(59%) were unchanged over the feedback period. Change in DMARD treatment was not significantly associated with the level of disease activity (χ^2 , $p=0.33$), or use of the feedback system (χ^2 , $p=0.50$).

DISCUSSION

According to the results of this study, the use of measurement feedback was associated with a reduction of RA disease activity in the feedback period as compared with the control period, in patients with high disease activity. The RADAI reduction of that subgroup corresponds with a clinically important difference¹⁰ and was nearly three times greater than for the subgroup of patients also with high disease activity, but no feedback use. In concordance, the subgroup with high disease activity and feedback use showed an improvement in the HAQ score and only a small increase in joint damage. In contrast, the subgroup of patients with high disease activity and no feedback use, had no improvement in the HAQ score, and a progression in joint damage that was twice as large. Thus it appears that the measurement feedback system contributed to a reduction of disease activity in patients with RA.

However, it is clear that a measurement feedback system is not an intervention that causes health effects, but drugs may do so. If the assumption of a measurement feedback system for RA is that the system is used to evaluate whether disease activity needs to be better controlled, or to ensure that disease activity is still under control, then it does not seem to be adequate that changes in DMARD treatment took place in less than half of the patients. Moreover, changes in DMARD treatment were not related to the level of disease activity at baseline or to feedback use. As the study was not designed to include drug strategy in the analysis, and as it is very difficult to judge the appropriateness of specific DMARD management for individual patients, it cannot be concluded that the feedback did not influence decision-making. But the most important conclusion that can be drawn is that not many changes in DMARD treatment occurred, even in patients with high disease activity. Also, systematic monitoring with the feedback system was much lower than was originally expected. One of the reasons for the suboptimal use of the measurement feedback system may be that available treatment guidelines^{16, 17} were not explicitly incorporated. Possibly, not all rheumatologists regarded suppression of disease activity as an explicit treatment goal. Also, prescription habits might be influenced by the “pyramid paradigm”, which has now been discarded.^{2, 17}

Another reason for the low use of the measurement feedback in the study may be the local healthcare system, where rheumatologists merely may have a consulting role for the general practitioner and see some of their patients with RA probably once yearly. Further, not all rheumatologists are used to outcome measures in clinical practice. Outcome measures are often appraised as “soft” data, unfamiliarity and difficulties with interpretation may lead to uncertainty if, and how, to use all the information.^{18–21} But the measurement of RA disease activity and disease consequences has improved substantially, and is within the ability of practising rheumatologists.²² The reasons for use and non-use of the measurement feedback system are currently being studied.

The major advantage of the study design with a control period followed by a measurement feedback (“intervention”) period is that the patients and rheumatologists are their own controls, and thus are optimally comparable. An important limitation is that it was not possible to “blind” the participants. However, an attempt was made to keep the patients unaware of outcome expectancy, and therefore the primary outcome was assessed by the patient. A bias from “knowing to be observed” (Hawthorne effect) might have occurred in both the control and feedback periods, and thus would not have introduced differential bias. Owing to the fact

that the rheumatologists were not “blinded”, prescription behaviour can theoretically be biased towards socially desired changes in DMARD treatment. However, as the number of patients with changes in DMARD treatment was low, this does not seem to have played an important part.

It must be noticed that the study of such a complex intervention as measurement feedback is difficult, mainly because (a) the intervention is mainly by the doctor, but important effects are expected in the patient; (b) the intervention is indirect, in the sense that in itself it will not influence disease activity; (c) disease activity is subject to many influencing factors at the same time—for example, on the levels of patient, treatment, treatment tolerance, social and physical surroundings, and prognostic factors of the disease; (d) the effects on outcome are expected to be relatively small, and the outcome measures used in RA may not be sensitive enough to detect small but relevant changes.

In primary care, several randomised controlled trials (RCTs) were performed on the effectiveness of computerised measurement feedback systems, with or without guidelines, mainly in patients having hypertension, diabetes, or anticoagulation need.^{23–29} From these studies it appears that computerised decision support systems (CDSS) were generally ineffective in changing doctor performance or health outcomes, probably for the same reasons as mentioned above. In arthritis, we could identify two RCTs on measurement feedback systems, dealing with disability.^{30, 31} Neither trial found any health gain. The studies used feedback at fixed times, and thus the feedback did not systematically coincide with visits or actual patient needs. It is clearly an advantage if relevant information is available at the moment of decision, and decision options are clear. This is the case with measurement feedback on drug dosing, of which “titration” of disease activity in RA is an example. A systematic review of computerised drug dosing systems included five RCTs dealing with outpatient maintenance anticoagulation treatment,³² of which one trial provided evidence that quality of initiation and control of warfarin treatment was improved by CDSS in comparison with usual care.³³ From this it can be concluded that until now there is no strong evidence of the effectiveness of measurement feedback systems, computerised drug dosing systems, or computerised guideline implementation systems in several chronic conditions in primary care. However, there is still a strong argument for the adoption of a measurement feedback system, or some other form of CDSS, in RA. As the primary target of RA treatment is the control of disease activity,¹⁷ the treatment has to be individually adjusted depending on the treatment effect and limiting toxicity. For reasons of patient care alone, but especially when using expensive treatments, it is most appropriate to monitor and document drug use, treatment effects, and toxicity in the individual patient.¹⁷

The current study provided limited evidence that a measurement feedback system is effective in RA, but the system was not intensively used. The measurement feedback system should be optimised to facilitate its use in clinical practice and its effectiveness should be studied using a carefully designed RCT. For these objectives it should be kept in mind that the primary target of measurement feedback is the rheumatologist, not the patient. A much more intensive training on the use of a measurement feedback system, the DAS as target measure, and the inclusion of explicit treatment guidelines will be necessary to increase the clinical use of measurement feedback and, possibly, to reduce disease activity for a larger number of patients.

ACKNOWLEDGEMENTS

We are indebted to the SCQM members and all other rheumatologists who took part in the study, especially Drs W Schmid (Aarau), P Hasler (Basel), T Lehmann and J Lory (Berne), G-A Davoine and F Perret

(Geneva), J Dudler (Lausanne), T Stoll (Schinznach), U Schlumpf (Lucerne), R Rüd, and B Christen (Winterthur). The authors thank Leanne Pobjoy for her help in preparing the manuscript.

The SCQM programme and the current trial were supported by grants from the Swiss Academy for Medical Sciences (SAMW), the Swiss Health Authorities (BAG), and the Böni Foundation.

Authors' affiliations

J Fransen, B A Michel, Department of Rheumatology and Institute of Physical Medicine, University Hospital Zurich, Switzerland
G Stucki, Department of Physical Medicine and Rehabilitation, University Hospital Munich, Germany
J Twisk, Institute of Research in Extramural Medicine, Faculty of Medicine, Free University Amsterdam, The Netherlands
A-M Chamot, Private practice, Morges, Switzerland
J-C Gerster, Department of Rheumatology, Physical Medicine and Rehabilitation, University Hospital Lausanne, Switzerland
T Langenegger, Adelheid Page Rehabilitation Hospital, Oberaegeri, Switzerland
M Seitz, Clinic for Rheumatology and Clinical Immunology and Allergology, University Hospital Berne, Switzerland

The members of the Swiss Clinical Quality Management in Rheumatoid Arthritis (SCQM) are: I Büchler, A-M Chamot, B Christen, G Dalvit, A Forster, P-A Guerne, P Hasler, T Langenegger, B A Michel, L Schmid, H Schwarz, M Seitz, A So, R Theiler, D van Linthoudt, P Villiger.

REFERENCES

- 1 **Stucki G**, Sangha O. Clinical quality management: putting the pieces together. *Arthritis Care Res* 1996;9:405-12.
- 2 **Moreland LW**, Russell AS, Paulus HE. Management of rheumatoid arthritis: the historical context. *J Rheumatol* 2001;28:1431-52.
- 3 **Uitz E**, Fransen J, Langenegger T, Stucki G. Clinical quality management in rheumatoid arthritis: putting theory into practice. *Swiss Clinical Quality Management in Rheumatoid Arthritis. Rheumatology (Oxford)* 2000;39:542-9.
- 4 **Stucki G**, Liang MH, Stucki S, Bruhlmann P, Michel BA. A self-administered rheumatoid arthritis disease activity index (RADAI) for epidemiologic research. Psychometric properties and correlation with parameters of disease activity. *Arthritis Rheum* 1995;38:795-8.
- 5 **Fries JF**, Spitz P, Kraines RG, Holman HR. Measurement of patient outcome in arthritis. *Arthritis Rheum* 1980;23:137-45.
- 6 **Prevo MLL**, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM. Modified disease activity scores that include twenty-eight joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum* 1995;38:44-8.
- 7 **Van Gestel AM**, Prevo MLL, van 't Hof MA, van Rijswijk MH, van de Putte LBA, van Riel PLCM. Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. *Arthritis Rheum* 1998;41:1845-50.
- 8 **Fransen J**, Langenegger T, Michel BA, Stucki G. Feasibility and validity of the RADAI, a self-administered rheumatoid arthritis disease activity index. *Rheumatology (Oxford)* 2000;39:321-7.
- 9 **Fransen J**, Häuselmann H, Michel B, Caravatti M, Stucki G. Responsiveness of the self-assessed rheumatoid arthritis disease activity index to a flare of disease activity. *Arthritis Rheum* 2001;44:53-60.
- 10 **Fransen J**, Forster A, Uebelhart D, Michel BA. Reliability and responsiveness of the RADAI, a self assessed rheumatoid arthritis disease activity index [abstract]. *Ann Rheum Dis* 2001;60(suppl 1):345.
- 11 **Rau R**, Wassenberg S, Herborn G, Stucki G, Gebler A. A new method of scoring radiographic change in rheumatoid arthritis. *J Rheumatol* 1998;25:2094-107.
- 12 **Sangha O**, Stucki G, Fossel AH, Katz JN. A simplified method to assess comorbidity in clinical and health service research of rheumatic diseases [abstract]. *Arthritis Rheum* 1995;38(suppl):177, abstract 148.
- 13 **SAS/STAT user's guide**. Version 6. 4th ed. Vol 2. Cary NC, USA: SAS Institute, 1990.
- 14 **Verbeke G**, Molenberghs G. *Linear mixed models in practice. A SAS-oriented approach*. New York: Springer Verlag, 1997.
- 15 **Kleinbaum DG**, Kupper LL, Muller KE. *Applied regression analysis and other multivariable methods*. Boston: PWS-KENT, 1988.
- 16 **ACR**. American College of Rheumatology Ad Hoc Committee on Clinical Guidelines. Guidelines for the management of rheumatoid arthritis. *Arthritis Rheum* 1996;39:713-22.
- 17 **Wolfe F**, Cush JJ, O'Dell JR, Kavanaugh A, Kremer JM, Lane NE, et al. Consensus recommendations for the assessment and treatment of rheumatoid arthritis. *J Rheumatol* 2001;28:1413-30.
- 18 **Deyo RA**, Patrick DL. Barriers to the use of health status measures in clinical investigation, patient care, and policy research. *Med Care* 1989;27(suppl):S254-68.
- 19 **Deyo RA**, Carter WB. Strategies for improving and expanding the application of health status measures in clinical settings: a researcher-developer viewpoint. *Med Care* 1992;30(suppl):S176-186.
- 20 **Golden WE**. Health status measurement. Implementation strategies. *Med Care* 1992;30(suppl):S187-195.
- 21 **Patrick DL**. Strategies for improving and expanding the application of health status measures in clinical settings. Discussion. *Med Care* 1992;30(suppl):S198.
- 22 **Pincus T**. Documenting quality management in rheumatic disease: are patient questionnaires the best (and only) method? *Arthritis Care Res* 1996;9:339-48.
- 23 **Goldberg HI**, Wagner EH, Fihn SD, Martin DP, Horowitz CR, Christensen DB, et al. A randomized controlled trial of CQI teams and academic detailing: can they alter compliance with guidelines? *Jt Comm J Qual Improve* 1998;24:130-42.
- 24 **Montgomery AA**, Fahey T. A systematic review of the use of computers in the management of hypertension. *J Epidemiol Community Health* 1998;52:520-5.
- 25 **Montgomery AA**, Fahey T, Peters TJ, MacIntosh C, Sharp DJ. Evaluation of computer based clinical decision support system and risk chart for management of hypertension in primary care: randomised controlled trial. *BMJ* 2000;320:686-90.
- 26 **Hetlevik I**, Holmen J, Kruger O. Implementing clinical guidelines in the treatment of hypertension in general practice. *Scand J Prim Health Care* 1999;17:35-40.
- 27 **Hetlevik I**, Holmen J, Kruger O, Kristensen P, Iversen H, Furuseth K. Implementing clinical guidelines in the treatment of diabetes mellitus in general practice. *Int J Technol Assess Health Care* 2000;16:210-27.
- 28 **Shiffman RN**, Liaw Y, Brandt CA, Corb GJ. Computer-based guideline implementation systems: a systematic review of functionality and effectiveness. *J Am Med Assoc* 1999;281:104-14.
- 29 **Johnston ME**, Langton KB, Haynes B, Mathieu A. Effects of computer-based clinical decision support systems on clinician performance and patient outcome. A critical appraisal of research. *Ann Intern Med* 1994;120:135-42.
- 30 **Rubenstein LV**, Calkins DR, Young RT, Cleary PD, Fink A, Koseoff J, et al. Improving patient function: a randomized trial of functional disability screening. *Ann Intern Med* 1989;111:836-42.
- 31 **Kazis LE**, Meenan RF, Anderson JJ, Swift MA. The clinical utility of health status information in rheumatoid arthritis (RA) patients: a controlled trial. *Arthritis Rheum* 1987;30(suppl):S12.
- 32 **Hunt DL**, Haynes B, Hanna SE, Smith K. Effects of computer-based clinical decision support systems on physician performance and patient outcomes. *JAMA* 1998;280:1339-46.
- 33 **Vadher B**, Patterson DL, Leaning M. Evaluation of a decision support system for initiation and control of oral anticoagulation in a randomised trial. *BMJ* 1997;314:1252-6.